Baseline measurements like body weight, BMI, and vital signs are taken to understand your starting point and determine if Tirzepatide is an appropriate option for your health needs
Clinical trial data from the NEJM Phase 2 study showed that gastrointestinal events were predominantly mild to moderate, occurred primarily during dose escalation, and were partially mitigated by starting at 2mg rather than 4mg
In humans gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are the only known insulin stimulating incretin hormones and are released from intestinal cells after food intake 2,3,4,5
Third, individual responses to GLP-1 class drugs vary some people are biologically more responsive than others
GLP-1 Receptor Agonists (GLP-1ras): Cardiovascular Actions and Therapeutic Potential
Our guide on how long peptides take to work explains how pharmacokinetic steady states are affected by treatment interruptions